 Although Millendo Therapeutics is a newer player in the biotech public market and the PWS market is small, it represents a so-far unmet need, Chico said in the note. About 10,000 patients suffer from PWS in the US, and there are no treatments available for the hallmark syndrome, hyperphagia, the analyst mentioned. 